Loading publications…
The last 5 uploaded publications
Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma
Emanuel Buehrer, Nina Glassée, Michal Kiciński, Oliver John Kennedy, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma. , DOI: https://doi.org/10.1016/j.ejcskn.2025.100727.
Article62 days ago1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, G.V. Long, V.G. Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Muhammad A. Khattak, M.S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, P. Lorigan, D. Grebennik, C. Krepler, Sandrine Marréaud, Stefan Suciu, C. Robert (2024). 1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.1163.
Article62 days agoPrognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassée, Michal Kiciński, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Emanuel Buhrer, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Mario Mandalà, Paul Lorigan, Sara Valpione (2024). Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 201, DOI: https://doi.org/10.1016/j.ejca.2024.113585.
Article62 days agoAdjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kiciński, Mario Mandalà, Madeline Pe, Georgina V Long, Victoria Atkinson, Christian U. Blank, Andrew Haydon, Stéphane Dalle, Adnan Khattak, Matteo S. Carlino, Andrey Meshcheryakov, Shahneen Sandhu, Susana Puig, Dirk Schadendorf, Rahima Jamal, Piotr Rutkowski, Alfonsus Johannes Maria van den Eertwegh, Corneel Coens, Dmitri Grebennik, Clemens Krepler, Caroline Robert, Alexander M.M. Eggermont (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. , 25(9), DOI: https://doi.org/10.1016/s1470-2045(24)00338-3.
Article62 days agoPrognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kiciński, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2023). Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 189, DOI: https://doi.org/10.1016/j.ejca.2023.04.016.
Article62 days ago